Chrifix Tablet 1 mg (Varenicline Salicylate)

Adult dosage

Set a quit date and start taking this medication 1 week before that date. Alternatively, you may start quitting between days 8 and 35 after starting this medication. This medication should be taken after meals with plenty of water. The recommended dosage is as follows: after dose titration over 1 week, take 1 mg twice daily. Days 1–3 0.5 mg once daily Days 4–7 0.5 mg twice daily Day 8 until the end of treatment 1 mg twice daily For patients who cannot tolerate the adverse reactions to this medication, the dose may be reduced temporarily or on an ongoing basis. The treatment period is 12 weeks. For patients who successfully quit smoking after the initial 12 weeks of treatment, an additional 12 weeks of treatment with this medication is recommended to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, gradual smoking cessation while taking this medication should be considered. Smoking should be reduced by 50% from the level before treatment within the first 4 weeks after starting this medication, and by an additional 50% within the following 4 weeks. Smoking should continue to be reduced so that complete cessation is achieved by week 12. Continue this medication for an additional 12 weeks, for a total treatment period of 24 weeks. Encourage patients to stop smoking sooner if they feel ready. Patients who fail to quit smoking after the initial 12 weeks of treatment or resume smoking after treatment should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who fail to quit during the initial 12 weeks of treatment or resume smoking after treatment. No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. No dose adjustment is necessary in patients with hepatic impairment. Because renal function is more likely to be reduced in elderly patients, care should be taken when selecting the dose, and monitoring renal function may be useful.

Children's dosage

Patients under 18 years of age: Use is not recommended because the safety and efficacy of this medication have not been established in children.

This medication is used to help with smoking cessation. Patients should monitor their mental health while taking this medication. Severe psychiatric symptoms such as depression, suicidal thoughts or behaviors, anxiety, hallucinations, and aggression may occur in some patients. If these symptoms arise, discontinue use immediately and consult a doctor. Particular caution is required for patients with a history of psychiatric disorders, and these should be disclosed to the doctor before taking this medication. Pregnant or nursing women should use this medication with caution and consult a doctor if necessary. Common side effects that may occur during treatment include nausea, headache, insomnia, abnormal dreams, anxiety, and changes in appetite. Exercise caution while engaging in activities requiring attention, such as driving or operating machinery, as drowsiness or impaired concentration may occur. Patients with cardiovascular diseases should report any heart-related abnormal symptoms that may appear during the use of this medication to their doctor immediately. There is little potential for interactions with other medications, but it is advisable to avoid or minimize alcohol consumption. This medication is not recommended for children or adolescents under 18 years old. Elderly patients may need dose adjustments based on kidney function, and those with impaired kidney function should consult their doctor. In case of overdose, contact a medical institution immediately for appropriate treatment. This medication should be stored in its original container and kept out of the reach of children.

• Suicidal ideation
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is best to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance

Pale blue, flat, oblong, film-coated tablet.

Package unit

28 tablets (14 tablets/Blister X 2)